Aspirin in the prevention of strokes

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Transient ischemic attack (TIA) and ischemic stroke are critical conditions requiring effective preventative treatments.
• Aspirin is a widely used antiplatelet medication for secondary prevention of vascular events.

Purpose of the Study:

• To evaluate the efficacy and safety of aspirin in reducing vascular events in patients with TIA and ischemic stroke.
• To determine the optimal aspirin dosage for balancing efficacy and tolerability.

Main Methods:

• Systematic review and meta-analysis of clinical trials comparing aspirin with placebo or other antiplatelet agents.
• Analysis of dose-ranging studies to assess the relationship between aspirin dose and clinical outcomes.

Main Results:

• Aspirin demonstrated a moderate yet significant reduction in the incidence of stroke, myocardial infarction (MI), and vascular mortality.
• Low-dose aspirin (50-325 mg daily) was found to be as effective as higher doses in preventing vascular events.
• Gastrointestinal side effects were less frequent with lower aspirin doses.
• Bleeding complications were observed even at the lowest aspirin doses and were not clearly dose-dependent.

Conclusions:

• Daily aspirin therapy, particularly at doses between 50 and 325 mg, is recommended for secondary prevention in patients with TIA and ischemic stroke.
• Lower aspirin doses offer a favorable balance of efficacy and tolerability, minimizing gastrointestinal adverse effects.
• Clinicians should remain vigilant for bleeding risks, as they are not eliminated even with low-dose aspirin therapy.